Modulating the PTPIP51 interactome in a HER2 amplified breast cancer cell line (SKBR3) with the novel small molecule LDC3/Dynarrestin led to significant alterations of several tumor relevant pathways. This evidence concerns the gene ERBB2 and breast cancer.